2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
Macaulay V, Middleton M, Protheroe A, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay J, LoRusso P, Mery-Mignard D, Soria J. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. Annals Of Oncology 2012, 24: 784-791. PMID: 23104723, PMCID: PMC3574548, DOI: 10.1093/annonc/mds511.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsDeoxycytidineDiarrheaDocetaxelDoxorubicinErlotinib HydrochlorideFemaleGemcitabineHumansLeiomyosarcomaMaleMelanomaMiddle AgedQuinazolinesReceptor, IGF Type 1Skin NeoplasmsSoft Tissue NeoplasmsTaxoidsTreatment OutcomeConceptsAdvanced solid tumorsInsulin-like growth factor receptorType 1 insulin-like growth factor receptorGrowth factor receptorIGF-IISolid tumorsDisease controlCommon adverse eventsFactor receptorIGF-1R antibodyDurable disease controlCohort C2Adverse eventsPartial responseCohort BDocetaxel administrationSteroid premedicationControl ratePK interactionsGrade 3IGF-BP3Blood samplesCohort C1PatientsAVE1642
2007
AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study
Shields A, Heath E, DeLuca P, Pilat M, Wozniak A, Gadgeel S, Puchalski T, Xu J, Liu Q, LoRusso P. AZD2171 in combination with various anticancer regimens: Follow-up results of a phase I multi-cohort study. Journal Of Clinical Oncology 2007, 25: 3544-3544. DOI: 10.1200/jco.2007.25.18_suppl.3544.Peer-Reviewed Original ResearchAnticancer regimensApparent PK interactionsCommon adverse eventsObjective tumor responseAdvanced solid tumorsPotential pharmacokinetic interactionsCell lung cancerMulti-cohort studyNovel study designPK parameter valuesStable diseaseAdverse eventsPartial responsePharmacokinetic interactionsTreatment armsClinical benefitSafety profileLung cancerPK interactionsTumor responseRecent trialsEfficacy dataAZD2171Unexpected toxicitiesCombination treatment